Original ArticlesCharacteristics and Outcomes of Psychiatric Inpatients With Severe Mental Illness and COVID-19 Experience From a COVID-19-Specific Acute Psychiatric Ward in IstanbulYalçin, Murat MD∗; Sönmez Güngör, Ekin MD∗; Ergelen, Mine MD∗; Beşikçi Keleş, Didem MD∗; Yerebakan Tüzer, Melike MD∗; Öcek Baş, Tuba MD∗; Güneş, Mustafa MD†; Genç, Davut MD∗; Kirşavoğlu, Betül MD‡; Metin, Merve MD§; Bülbül, Alper MD∗; Kayacan, Asli MD∗Author Information ∗Erenköy Mental and Nervous Diseases Training and Research Hospital, University of Health Sciences, Istanbul †Erzurum Region Training and Research Hospital, Erzurum ‡Bulancak State Hospital, Giresun §Gönen State Hospital, Balikesir, Turkey. Send reprint requests to Murat Yalçin, MD, Erenköy Mental and Nervous Diseases Training and Research Hospital, University of Health Sciences. 19 Mayis, Sinan Ercan Cd. No:23, 34736 Kadiköy/Istanbul, Turkey. E-mail: [email protected]. All participants gave informed consent. The study has been carried out in accordance with 1964 Declaration of Helsinki and its later amendments and was approved by the ethics committee of Erenköy Mental Health and Nervous Diseases Training and Research Hospital and COVID-19 Scientific Review Board of the Turkish Ministry of Health. The Journal of Nervous and Mental Disease: December 2021 - Volume 209 - Issue 12 - p 884-891 doi: 10.1097/NMD.0000000000001450 Buy Metrics Abstract Recent studies indicated that psychiatric inpatients with severe mental illness (SMI) are at a greater risk of morbidity and mortality from COVID-19. However, there is still little data about the impact of comorbid COVID-19 infection on the course and outcome of acute exacerbations in this population. We conducted a prospective historically matched case control study. The sociodemographic and clinical characteristics of acute psychiatric inpatients with SMI and comorbid COVID-19 (n = 21) were compared with those of historically-matched non-COVID-19 controls with SMI (n = 42). The outcomes for acute inpatients with SMI and COVID-19 were also investigated. The new-onset SMI rate was relatively higher (23.8%) in the COVID-19 group, which has characteristics similar to those of the non-COVID-19 group except for working status (p < 0.05). The COVID-19 group had a high rate of relapse (47.6%) within 6 months of discharge. Our study suggests that patients with SMI who contracted SARS-CoV-2 may have a higher rate of new-onset mental disorder. Considering the high rate of relapse during the pandemic, chronically ill patients with SMI and COVID-19 should be closely monitored after discharge. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.